Lv1
30 积分 2024-11-11 加入
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
1天前
待确认
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial
1天前
已完结
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
1天前
已完结
Deep resolution of clinical, cellular and transcriptomic inflammatory markers of psoriasis over 52 weeks of interleukin-17A inhibition by secukinumab
2天前
已完结
Are IL-17 inhibitors superior to IL-23 inhibitors in reducing systemic inflammation in moderate-to-severe plaque psoriasis? A retrospective cohort study
2天前
已完结
Risk factors and early detection of joint damage in patients with psoriasis: a case–control study
5天前
已完结
Novel Digital Biomarkers for Fine Motor Skills Assessment in Psoriatic Arthritis: The DaktylAct Touch-based Serious Game Approach
1个月前
已完结
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
1个月前
已完结
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
1个月前
已完结
Deucravacitinib (Sotyktu™) for plaque psoriasis
1个月前
已完结
皖公网安备34019202002308
